Commercialization: Page 14

PharmaVoice Team/PharmaVoice

Commercial Influencers

Influencers have the power to positively change the status quo because of their authority, knowledge, position, or relationship with their audience. According to the global consultancy Evaluate, the impact of COVID-19 has so far wiped $7.85 billion off forecasts for biopharma sales in 2020, with ...
By PharmaVoice Team • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Roshawn Blunt — Optimizing a Strategic Plan

Given cell and gene therapies are typically personalized medicines, they come with outlier pricing and other unique commercialization challenges that differ from other large and small molecule therapies. Roshawn Blunt, a respected biotech consultant, was inspired by President John Adams, who in 1...
By Roshawn Blunt • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Greg Skalicky — Understanding the Commercial Lifecycle

By building a complete commercial platform, we are able to take a broad view of how market and product complexities impact operations. With a wide breadth of clinical and commercial experience, Greg Skalicky, chief revenue officer of EVERSANA, has a keen understanding of the entire product lifecy...
By Greg Skalicky • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

SHOWCASE: Artificial Intelligence: Driving Drug Innovation With AI

The global AI market has been showing rapid growth as major pharmaceutical and medical technology companies invest heavily in internal and external AI partnerships. According to some reports, more than 50% of executives expect broad scale AI adoption by 2025. Further, revenue generated through AI...
By PharmaVoice Team • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Case Study: Leveraging AI for Meaningful Clinical Trials

Clinical trial sponsors seeking to develop new drugs and therapies face unique challenges, particularly when it comes to understanding patient dosing and response to therapy. This aspect can be difficult, as patients often: Do not take their medicine regularly, or at all Take creative measures to...
By Rich Christie • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

How AI Can Improve Understanding of Patient's Behavior and Symptoms

Running and managing clinical trials, at the most basic level, is about creating a foundation to get the best possible data. While a great deal of thought goes into recruiting the right patients and developing the most effective protocols, initiatives designed to improve the experience for the pa...
By Michelle Marlborough • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

5 Steps to Intelligent Omnichannel Engagement

The future of HCP engagement in the post-pandemic world isn’t clear. But in the wake of pharma’s forced digital migration, the need for an effective omnichannel strategy is. Luckily, most commercial teams already have a strong data and analytics infrastructure in place and are beginning to activa...
By Matthew Van Wingerden • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Technology-Driven Pharmacovigilance Operations

Improving Data Quality and Compliance while Reducing Cost with AI Traditionally, the pharmacovigilance (PV) function has been responsible for collecting, assessing, and reporting safety information to health authorities, sites, and other stakeholders. Companies have invested in safety systems to ...
By Dinesh Kasthuril • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

AI and Drug Discovery

Discovering and bringing new drugs to market is notoriously slow and costly for a reason. Science moves slowly because of the incredibly complex nature of human biology and the difficulty of sluggish recruitment of clinical trials. And in spite of greater investments in R&D by pharmaceutical ...
By Claire Bonaci • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

The Accessibility of AI: Innovation at Your Fingertips

The availability of datasets keeps growing exponentially. With this we are witnessing an escalation of available new life-altering systems. Some of these tools are highly autonomous and can perform functions with little to no human intervention. Self-driving cars, rockets that land upright on dro...
By Max Divak • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

AI-Driven Marketing

We have all seen those digital banners that are somehow related to what we’re looking at online and appear to follow us wherever we are. Don’t worry, there is nothing ominous at play and the government is not listening to our conversations through our devices. But this is not completely coinciden...
By J.P. Maranzani • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Leveraging AI to Slingshot Drugs from Lab to Market

The science of clinical development continually astounds even those of us intimately connected to it. We recognize that our overarching industry mandate — to develop and deliver safe and effective new therapies to fight and cure disease — must be continually informed by new thinking and tools if ...
By Malai Sankarasubbu • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

The Salesforce of the Future

COVID-19 is fast-tracking the industry’s slow move from fewer in-person HCP visits to digital and virtual approaches. COVID-19 has driven vast changes in what healthcare providers need and value from pharma companies, and as a result, the industry is striving to develop new ways to engage with ph...
By Robin Robinson • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

SHOWCASE: Patient Solutions: The Changing Face of Patient Engagement

Digital technologies are changing the healthcare landscape, creating opportunities for patient-support programs, patient monitoring and self-management. There is massive demand for patient-engagement solutions, with predictions that the market for such solutions will reach $30.36 billion by 2026....
By PharmaVoice Team • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Advancing Beyond the Traditional Patient Adherence Model

Delivering value in the era of empowered patients renders the one-size-fits-all patient services program obsolete. Not every treatment journey is consistently linear within a disease state because patients take different paths to medication adherence. For example, one patient may be compliant whe...
By Maria Kirsch • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Social Connection Is Possible in a Time of Physical Distancing

In this time of physical distancing, technology often seems like the go-to solution for helping people connect. However, data linking social media and depression, as well as research pointing to social divisiveness online, might give us pause. Recent survey results found most Americans believe th...
By Amrita Bhowmick • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Listening to the Patient for Better Outcomes

The aim of drug development is to improve patient outcomes. Historically, clinical research has been driven by researchers, with little or no input from patients, contributing to many of the challenges and inefficiencies we see in today’s clinical trials. Some of these challenges include low enro...
By Gretchen Goller • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Speak Out: The Power of Virtual Patient Simulation in CME

Simulation as we think of it today has been used in medical education since the 18th century,1 and has continued to evolve into realistic and medically accurate physical and digital solutions designed to allow learners to simulate a scenario-based encounter with a patient in a safe environment. V...
By Martin Warters • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Executive Perspective: AI With a Healthcare IQ: A Conversation with Lucas Glass and Andrew Ploszay

Since the term was first coined in 1955, “artificial intelligence" (AI) has led to significant advances across industries. From robotics to automobiles, to digital personal assistants, and even online shopping. In healthcare, AI has enabled many successes, but a few noteworthy failures have made ...
By Lucas Glass • Oct. 1, 2020
PharmaVoice Team/PharmaVoice

Letter from the Editor

What’s Next … Over the past several months, I, like everyone else, have wondered what’s next? What’s next if there’s not a vaccine approved soon? And, even if a vaccine is approved, how does that play out? What happens if there’s a next wave of COVID-19 that coincides with flu season? The what if...
By Taren Grom • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

Upfront

Bristol Myers Squibb Commits $300 Million to Health Equity and Diversity and Inclusion Efforts Bristol Myers Squibb and the BMS Foundation are investing $300 million over the next five years to accelerate and sustain its diversity, equity, and inclusion efforts. Specifically, the company will foc...
By PharmaVoice Team • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

HealthTech

Amwell Telehealth Use Swells During Pandemic Trend Watch: Technology Rises to the Challenges of COIVD-19 Amwell, a national telehealth company, which has been gaining app usage since the onslaught of COVID-19, has hired a new Chief Technology Officer Serkan Kutan. Mr. Kutan who comes from executi...
By PharmaVoice Team • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

Artificial Intelligence

SOPHiA Genetics’ First Multimodal Approach to Predict COVID-19 Disease Evolution Trend Watch: AI Technology Helps in the Fight Against COVID-19 Health-tech company SOPHiA Genetics, specializing in data-driven medicine, has launched a first-of-its-kind multimodal solution to predict COVID-19 disea...
By PharmaVoice Team • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

Last Word

Changing the Patient–Scientist Dialogue Paul Kidwell, Senior Public Relations/Patient Advocacy Consultant & Podcaster, for the life-sciences industry provides an insider’s view into the need for increased communication between patients and scientists. PV: What has been your experience in term...
By Paul Kidwell • Sept. 1, 2020
PharmaVoice Team/PharmaVoice

SHOWCASE: Big Data: Big is Better: The Importance of Data in Industry Advances

Big data is big business, and for the life-sciences and healthcare industries it’s playing an important role in informing everything from R&D to commercialization. With the growth of digital healthcare, it is estimated that the amount of data the industry is collecting is increasing by around...
By PharmaVoice Team • Sept. 1, 2020